Electroporation is the microbiology technique that uses an electrical pulse to create temporary pores in cell membranes through which substances such as nucleic acids can pass into cells. Electroporation can be used for all cell types including mammalian, bacteria, algae, plant, and yeast. It uses an accurately pulsed electrical current to create temporary pores in the cell membrane through which the molecules can then pass. Some applications of electroporation include, Deoxyribonucleic acid transfection or transformation, direct transfer of plasmids between cells, induced cell fusion, trans-dermal drug delivery, and cancer tumor electro chemotherapy and gene therapy
Global electroporation instrument market is estimated to be valued at US$ 232.19 Mn in 2022 and is expected to reach US$ 328.53 Mn by 2030, exhibiting a CAGR of 4.4% during the forecast period (2022-2030).
Figure 1. Global Electroporation Instruments Market (%) in Terms of Value, By Region, 2022
Increasing prevalence of cancer is the major factor that is expected to drive growth of the global electroporation instruments market over the forecast period.
Increasing prevalence of cancer, is the major factor that is expected to drive growth of the global electroporation instruments market over the forecast period. For instance, according to the World Health Organization report 2020, cancer was the leading cause of death in the world, accounting for around ten million deaths in 2020 worldwide. In terms of new cancer cases worldwide, the most common were: 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.4 million cases of prostate cancer, 1.20 million cases of skin cancer, 1.93 million cases of coon & rectum cancer, and 1.09 million cases of stomach cancer. According to the American Cancer Society 2020 report, around 1.8 million new cancer cases were diagnosed and 606,520 deaths by cancer in the U.S. in 2020 were reported.
|Base Year:||2021||Market Size in 2022:||US$ 232.19 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.4%||2030 Value Projection:||US$ 328.53 Mn|
Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems
|Restraints & Challenges:||
Figure 2: Global Electroporation Instruments Market Share (%), by Product Type, 2022
Increasing product approvals and launches are expected to drive growth of the global electroporation instruments market during the forecast period
Increasing product approvals and launches are expected to drive growth of the global electroporation instruments market during the forecast period. For instance, on April 2, 2022, Thermo Fisher Scientific Inc., an American supplier of scientific instrumentation, reagents and consumables, and software services announced the launch of Gibco CTS Xenon Electroporation System. The product is intended to enable the development of cell therapies. Moreover, on June 25, 2020, MaxCyte, a global clinical-stage cell-based medicines and life sciences company, announced the launched of the first product in its new and expanded ExPERT disposables line. The R-1000 cuvette can process a volume of up to one mL, or up to 200 million cells, and offers greater versatility for companies developing cell therapy drugs, as well as those advancing early drug discovery. These new cuvette designs can be used across the entire range of MaxCyte's electroporation instrumentation.
Global Electroporation Instruments Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regard to the transportation and distribution of healthcare products. However, the COVID-19 pandemic might have a positive impact and boost growth of the global electroporation instruments market over the forecast period, owing to the use of electroporation in delivering vaccines and drugs for the treatment of COVID-19. For instance, according to an article published in Eureka, blog of Charles River Laboratories Inc., U.S., on January 13, 2021, as the race for a COVID-19 vaccine intensified, researchers began looking for better, more effective drug delivery systems. Electroporation is one such in vivo drug delivery technologies. It has been demonstrated that electroporation has a significant impact on vaccine immunogenicity and efficacy. This is due to the fact that it has the potential to increase antigen delivery by up to 1,000-fold when compared to naked DNA delivery technologies alone. The increase in antigen delivery results in a greater magnitude of immune response as well as higher response rates when compared to DNA delivery via direct injection alone.
Electroporation Instruments Market Restrains:
High cost associated with electroporation instruments, lack of skilled professionals, and stringent government regulations are expected to hinder growth of the global electroporation instruments market over the forecast period. According to the data published in Inverse Journal 2020, the electroporation instrument may cost in the range of US$ 3,000 to US$ 11,000
Major players operating in the global electroporation instruments market are Bio-Rad Laboratories, Inc, Thermo Fisher Scientific Inc., BTX ( a division of Harvard Bioscience), Celetrix, LLC., Gamma Biosciences, Merck KgaA, Eppendorf SE, MaxCyte, Inc. BEX CO.,LTD., Lonza, Altogen Biosystems, Ala Scientific Instruments, Inc., BioEra Life Sciences Pvt. Ltd., and Ichor Medical Systems
Electroporation is a useful molecular biology technique that allows for non-chemical transformation of bacteria and yeasts as well as transfection of tissue culture cells (e.g. mammalian cells). Electroporation systems deliver short bursts of a high-intensity electric field to cells. The electrical field makes the cell membrane more permeable. As a result, chemicals such as drugs and genetic material can pass through the cell membrane, which would otherwise be impermeable. Due to its ease of use and efficacy, electroporation is a popular method for introducing foreign genes into target cells. In addition to direct gene introduction, electroporation allows for the direct transfer of plasmids between cells or species—for instance, from bacteria to yeast. Extensive research is ongoing on the use of electroporation to deliver medicines and vaccines directly to the cells of living organisms. Electroporation systems are commonly used for the treatment of cancer through vaccine delivery, gene delivery or drug delivery that is electrochemotherapy, for instance bleomycin Vaccine delivery can also be used for treatment of infectious disease such as Human immunodeficiency virus (HIV).
Key players operating in the global electroporation instruments market are focusing on growth strategies such as rebranding and agreements which is expected to drive the market growth during the forecast period. For instance, The Company is now operating as Eppendorf SE with immediate effect. Eppendorf AG was restructured into a European Company (Societas Europaea, SE) under the name Eppendorf SE, effective October 19, 2021. This change of legal form to an SE does not affect any existing business relationships with their partners; existing contractual relationships in particular continue unchanged. Moreover, On July 15, 2022, MaxCyte, Inc. had announced the Strategic Platform License (SPL) signed with LG Chem Ltd., a global diversified chemical company .Under the terms of the agreement, LG Chem will receive non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to platform license fees and program-related revenues.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.